Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687867 · ClinicalTrials.gov registry record
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 56,039
- Enrollment target
NCT02687867 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 56,039 participants.
The verdict
NCT02687867 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 56,039 participants
- Enrollment target
Study Summary
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
Interventions
- DRUG Dabigatran (Pradaxa)
- DRUG Vitamin K antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56,039 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02687867
The ClinicalTrials.gov registry entry for NCT02687867 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56,039 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran (Pradaxa) is the first listed.
NCT02687867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02687867 about?
NCT02687867 is a clinical study titled "Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist". To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
What is the current status of trial NCT02687867?
This trial is currently completed. The enrollment target is 56,039 participants. The study started on 2016-02-12. Estimated completion is 2016-03-01.
What interventions are being tested in trial NCT02687867?
The interventions under investigation include: Dabigatran (Pradaxa) (DRUG), Vitamin K antagonist (DRUG).
Who is sponsoring clinical trial NCT02687867?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.